CN101209271B - Medicinal composition for preventing helicobacter pylori - Google Patents
Medicinal composition for preventing helicobacter pylori Download PDFInfo
- Publication number
- CN101209271B CN101209271B CN2006101616393A CN200610161639A CN101209271B CN 101209271 B CN101209271 B CN 101209271B CN 2006101616393 A CN2006101616393 A CN 2006101616393A CN 200610161639 A CN200610161639 A CN 200610161639A CN 101209271 B CN101209271 B CN 101209271B
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- helicobacter pylori
- eluent
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention provides an extract which is extracted from geraniaceae plants, an extraction method of the extract, an application of the extract in the prepration of anti-helicobacter pylori infection drugs and the drugs for the treatment or prevention of gastrointestinal diseases which are caused by helicobacter pylori infection, and an application of the composition in the preparation of drugs for the treatment of hepatitis.
Description
One, technical field
The invention belongs to field of medicaments, relate in particular to extracting method and the application and the application in preparation treatment hepatitis medicament in the digestive tract disease medicine that the preparation anti-helicobacter pylori infects and treatment or prevention helicobacter pylori infections cause of extraction obtains from Mang cattle Seedling section plant a kind of extract and this extract.
Two, background technology
Nineteen eighty-three Australia scholar's Warren (Warren) and Marshall (Marshall) are isolated helicobacter pylori (Helicobacter pylori) first from gastric mucosa, abbreviation Hp.
(Helicobacter pylori Hp) is a kind of Gram-negative spiral bacteria to helicobacter pylori.Data shows, the whole world has the population more than 50% to infect helicobacter pylori approximately, the infection of developing country is particularly serious, wherein adult's infection rate reaches 60～80%, helicobacter pylori is the main pathogenesis of acute and chronic gastritis and stomach, duodenal ulcer, and closely related with the morbidity of gastric cancer stomach function regulating mucosa-associated lymphoid tissue (MALT) malignant lymphoma.Recently, World Health Organization (WHO) is classified as I class carcinogen with Hp, and it plays a leading role in the gastric cancer development.The scheme that present popular treatment Hp infects is to take the triple therapy that proton pump inhibitor (PPI) adds two kinds of antibiotic (clarithromycin, amoxicillin, tetracycline, metronidazole etc. select two kinds) simultaneously.The main factor that influences triple therapy is considered to the drug resistance of Hp to antibacterial; Another serious problems are that proton pump inhibitor can bring out dyspepsia, and a large amount of antibacterial then cause the serious destruction of flora in the digestive tract.
Therefore, seek efficient, the safe active medicine of anti-Hp that has and become an important and urgent task.
Three, summary of the invention
The purpose of this invention is to provide a kind of new pharmaceutical composition, the extract of this pharmaceutical composition for from Mang cattle Seedling section plant, obtaining through extraction, feature is a chemical compound 1 in this extract, 2,3,6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose (1,2,3, the percentage ratio that 6-Tetra-O-galloyl-β-D-glucose) accounts for the extract gross mass is 1%-20%; Be preferably chemical compound 1,2,3 in this extract, (1,2,3, the percentage ratio that 6-Tetra-O-galloyl-β-D-glucose) accounts for the extract gross mass is 2%-15% to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose; Most preferably be chemical compound 1,2,3 in this extract, (1,2,3, the percentage ratio that 6-Tetra-O-galloyl-β-D-glucose) accounts for the extract gross mass is 3%-10% to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.
Another object of the present invention provides the preparation method of said extracted thing.
Preparation method of extract of the present invention is: the plant that is selected from Mang cattle Seedling section is adopted ethanol merceration or reflux, extract, after crushed, be concentrated to and do not have the alcohol flavor, go up macroporous resin behind the thin up, water, concentration are that the ethanol eluent eluting of 10-90% separates, and collection merging ethanol part eluent is concentrated into to be done and get.
It is that HPD100, HPD400, HPD600 are preferably HPD100 that macroporous resin can be selected from model.
The concentration of alcohol of merceration or backflow is 40-80% in the leaching process, and preferred concentration is 50-70%, most preferably is 60%.
Eluent concentration is the ethanol of 10%-90%, is preferably the ethanol of 40-60%, most preferably is 50% ethanol eluent.
The preferred for preparation method is: get that above-mentioned medical material aerial parts or herb are pulverized after 60% ethanol merceration or reflux, extract, three times, the extracting solution merging is concentrated into nothing alcohol flavor, thin up, last HPD100 macroporous resin, water, any concentration ethanol of 10-90% is eluting respectively, through the uv absorption check, collect 10-90% ethanol eluent, merging is concentrated into dried that solid content is extract.
Chemical compound 1,2,3 in the extract that obtains by said method, (1,2,3,6-Tetra-O-galloyl-β-D-glucose) account for the total extract mass percent is 1%-20% to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.
The checking of uv absorption described in this method purpose is to collect the eluent that there is uv absorption at wavelength 275nm place.At the 275nm place uv absorption is arranged all through uv absorption checking 10-90% ethanol eluent, the eluent of 50% ethanol is the strongest in 275nm place uv absorption.Merceration or reflux, extract, adopt the conventional extraction time extraction in this area in the extracting method, and ethanol extract concentration is preferably 50-70%, most preferably is 60%.Composition is mainly Polyphenols and flavones ingredient in the extract of the present invention.
Chemical compound 1,2,3 in the extract, 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose (1,2,3, the content of 6-Tetra-O-galloyl-β-D-glucose) adopts the HPLC method to measure, and concrete condition determination is as follows:
Chromatographic column: 18 alkyl silica gel bonding phase
Detect wavelength: 275nm
Mobile phase: acetonitrile-2% glacial acetic acid aqueous solution (14: 86)
Sample size: 20ul
Flow velocity: 1.0ml/min
Another object of the present invention provide the said extracted thing the preparation anti-helicobacter pylori infect and the medicine of the digestive tract disease that treatment or prevention helicobacter pylori infections cause in application.
A further object of the invention provides the application of said extracted thing in preparation treatment hepatitis medicament.
Useful especially is that this extract can be prepared into the pharmacy regular dosage form by the conventional preparation method of pharmacy with the pharmacy acceptable auxiliary in described application.Pharmacy can be accepted filler that adjuvant comprises the pharmacy routine, wetting agent, binding agent, disintegrating agent, excipient, antioxidant, flavoring agent etc.The pharmacy regular dosage form comprises wherein preferred tablet, capsule such as tablet, capsule, drop pill, pellet, powder, granule.
The inventor is by a large amount of pharmacology tests, confirmed described extract in vivo external enwergy effectively suppress the growth of helicobacter pylori, and confirm that by the whole animal test this extract can effectively suppress the generation of the stomach ulcer that helicobacter pylori brings out.It is generally acknowledged that helicobacter pylori is after the gastric mucosa field planting, can cause chronic, superficial gastritis through several weeks or several months, may develop into duodenal ulcer, gastric ulcer, lymphocytic hyperplasia gastric lymphoma, chronic atrophic gastritis etc. behind several years or the many decades, and these all are the risk factors that cause that gastric precancerous lesion or gastric cancer takes place.Therefore can believe that extract of the present invention can effectively prevent the generation of tumor stomach and stomach precancerous lesion effectively suppressing helicobacter pylori when treating the gastric ulcer that is brought out by helicobacter pylori.
Hepatitis of the present invention comprises viral hepatitis such as hepatitis B, hepatitis C, also comprises because of taking in chemical substance or taking the hepatic injury of the improper chemical that causes of medicine, comprises drug induced hepatic injury, alcoholic liver injury etc.The inventor confirms that by pharmacology test this extract can reduce transaminase's rising that hepatic injury causes, and liver is had protective effect.It should be noted that this extract alt-reducing and liver-protecting effect the best in preferable range, show to have mutual synergism between the extract functional component.
Above-mentioned concrete beneficial effect describes in detail by embodiment 5,6,7,8.
Mang cattle Seedling of the present invention section plant is for mainly being selected from one or more the plant in thick root Herba Erodii (Geranium dahuricum) in the Mang cattle Seedling section plant, Carolina Cranesbill Herb (Geranium caroliniznum), Herba Geranii eriostemonis (Geranium eriostemon), G.vlassouianum Fisch. (Geranium vlassorianum), Geranium tsingtauense Yabe (Geranium tsingtauense), the Geranium macrorrhizum Zdravets (Geranium macrorrhizum).
Chemical compound 1,2,3 of the present invention, 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose (1,2,3,6-Tetra-O-galloyl-β-D-glucose) its structural formula is as follows:
1，2，3，6-Tetra-O-galloyl-β-D-glucose
Stomach precancerous lesion of the present invention is meant that gastric cancer last stage pathological changes comprises chronic superficial gastritis, intestinal epithelial metaplasia and dysplasia etc.Digestive tract disease of the present invention mainly refers to acute and chronic gastritis, superficial gastritis and stomach, duodenal ulcer and tumor stomach that helicobacter pylori causes and the precancerous lesion of stomach.
The specific embodiment
The following example is used for the content of the present invention of further explaining, but does not mean that any limitation of the invention.
Embodiment 1
Get thick root Herba Erodii (Geranium dahuricum) 100g, pulverize, add the ethanol of 8 times of amounts 40%, reflux, extract, three times, each 2 hours.The elimination medicinal residues merge 3 extracting solution, be concentrated into 1/6 volume, to there not being the alcohol flavor, thin up filters HPD100 macroporous resin on the filtrate to twice medical material volume, water, 10%, 50%, 90% ethanol is eluting respectively, through the uv absorption checking, collect merging 10%, 50%, 90% ethanol eluent, be concentrated into dried that solid content 2.13g is this extract.Wherein chemical compound 1,2,3, and (1,2,3,6-Tetra-O-galloyl-β-D-glucose) accounts for 2.2% of extract gross mass to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.
Embodiment 2
Get Carolina Cranesbill Herb (Geranium caroliniznum) 1kg, pulverize, the ethanol room temperature merceration that adds 8 times of amounts 60% extracts three times, soaks 24 hours at every turn.The elimination medicinal residues merge 3 extracting solution, are concentrated into 1/7 volume, and ethanol is removed in volatilization, last HPD100 macroporous resin, water, 30%, 50%, 90% ethanol is eluting respectively, verifies through uv absorption, collect merging 30%, 50%, 90% eluent, be concentrated into dried that solid content 22.7g is this extract.Wherein chemical compound 1,2,3, and (1,2,3,6-Tetra-O-galloyl-β-D-glucose) accounts for 4.6% of extract gross mass to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.
Embodiment 3
Get Geranium tsingtauense Yabe (Geranium tsingtauense) 200g, pulverize, add the alcohol reflux three times of 8 times of amounts 80%, each 2 hours.The elimination medicinal residues merge 3 extracting solution, be concentrated into 1/6 volume, to there not being the alcohol flavor, thin up filters HPD100 macroporous resin on the filtrate to twice medical material volume, water, 20%, 50%, 70% ethanol is eluting respectively, through the uv absorption checking, collect 20%, 50%, 70% ethanol eluent, be concentrated into dried that solid content 4.18g is this extract.Wherein chemical compound 1,2,3, and (1,2,3,6-Tetra-O-galloyl-β-D-glucose) accounts for 11.4% of extract gross mass to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.
Embodiment 4
Get Geranium macrorrhizum Zdravets (Geranium macrorrhizum) 100g, pulverize, the ethanol room temperature merceration that adds 8 times of amounts 60% extracts three times, soaks 24 hours at every turn.The elimination medicinal residues merge 3 extracting solution, are concentrated into 1/7 volume, and ethanol is removed in volatilization, last HPD100 macroporous resin, water, 50%, 90% ethanol is eluting respectively, verifies through uv absorption, collect merging 50%, 90% ethanol eluent, be concentrated into dried that solid content 2.58g is this extract.Wherein chemical compound 1,2,3, and (1,2,3,6-Tetra-O-galloyl-β-D-glucose) accounts for 5.7% of extract gross mass to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.
Embodiment 5 extract anti-helicobacter pylori experiment in vitro of the present invention
1. experiment material:
Extract: adopt the method preparation of embodiment 4, chemical compound 1,2,3, (1,2,3,6-Tetra-O-galloyl-β-D-glucose) accounts for 5.7% of extract gross mass to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.
Experimental strain: helicobacter pylori (Helicobacterpylori, Hp) reference culture ATCC 43504, ATCC49503 preserve center (American Type Culture Collection from U.S.'s strain, ATCC), Hp SS1 bacterial strain is from microorganism institute of University of New South Wales, all the other helicobacter pylori clinical strains digest the disease institute from Shanghai, after RUT, smear Gram, oxidase and catalase are accredited as the positive, the pure culture of going down to posterity, obtained strains is as experimental strain.
2. experimental technique
1) strain culturing method
Adopt little aerobic bag (available from Fudan University) to carry out the strain culturing of Hp.
2) biological activity determination method
Adopt agar dilution measure minimum inhibitory concentration for test agent (minimal inhibitoryconcentration, MIC).
Agar dilution is measured MIC:
(A) preparation of medicine flat board is at first with the extract and the medicinal dimethyl sulfoxide of positive control (DMSO) the solution mother solution that is mixed with 3.2mg/ml of test, after the filtration sterilization, and reuse sterilized water doubling dilution to 320,160,80,40,20,10,5,2.5,1.25,0.6 with the concentration series of 0.3 μ g/ml, the concentration of DMSO in medium is less than 1%.The testing drug solution that 1ml is prepared and the abundant mixing of 9ml Colombia culture medium that is incubated in 50 ℃ are cast cooling, and culture medium is Mueller-Hinton agar (Difco Co.).
(B) switching experimental bacteria (being coated with bacterium) with microscale sampler draw dilution good 1? 0
8The bacteria suspension 0.1ml of CFU/ml Hp spreads upon the culture dish surface equably, is inverted in the 37 O-C drying bakers to take out behind the 15min, and purpose makes the agar surface drying, and is standby.
(C) determine that MIC (contains culture dish to be measured: 85%N at little aerobic bag
2, 10%CO
2And 5%O
2) in, be incubated 37 ℃ and cultivated 72 hours, observe the Hp growing state, be minimum inhibitory concentration (minimal inhibitory concentration, MIC) value with the sample least concentration that does not have bacteria growing fully.The positive control medicine is ampicillin (Ampicillin).All test triplicate.
3. experimental result
Table 1. extract of the present invention is to the minimum inhibitory concentration experiment of helicobacter pylori
+: can suppress fully the growth of bacterium-: can not suppress the growth of bacterium fully
Table 2. ampicillin (μ g/ml) is to the minimum inhibitory concentration experiment of helicobacter pylori
+: can suppress the growth of bacterium fully;-: can not suppress the growth of bacterium fully.
4. discussion of results
Experiment in vitro shows: extract of the present invention has very strong anti-helicobactor pylori activity, and action intensity approaches the positive drug ampicillin.Extract concentrations of the present invention can suppress the growth of all Hp when being 5 μ g/ml, especially the growth inhibited to H.pylori 006, H.pylori 018 is the most obvious, and it is 1.25 μ g/ml that minimal inhibitory concentration (MIC) reaches.The results are shown in Table 1, table 2.
Anti-helicobacter pylori experiment in the body of embodiment 6 extracts of the present invention
This experiment divides two stages to carry out, and the phase I is set up Hp mice infected model, and second stage is carried out pharmacodynamics test.
1, the foundation of helicobacter pylori (Hp) mice infected model
1) cultivation of Hp bacterial strain
Hp SS1 bacterial strain is from microorganism institute of University of New South Wales.-70 ℃ of frozen strains are recovered containing on the Columbia agar plate of 5% horse blood, and transferred species is in having added 15% horse serum and antibiotic brain-heart-infusion.Cultivate amplification under little aerobic condition ,-80 ℃ of preservations are put in packing after urease, catalase, oxidase test and smear Gram's staining are identified.Before the inoculation antibacterial was cultivated 24-48 hour on the Skirrow selective medium, after evaluation and observing the antibacterial vigor, antibacterial is centrifugal in PBS liquid, washing is mixed with 1x10 with improved broth medium at last
9The bacterial suspension of CFU/ml, inoculation experiments animal immediately.
2) the Hp bacterial strain is in the intravital inoculation of mice
Laboratory animal is no special pathogen level (SPF) C57BL/6 mice, Mus 6-8 in age week, body weight 18-20g.Entrust Chinese Academy of Sciences's Shanghai Experimental Animal Center to raise.The filling stomach gives every mice 0.5ml and (contains 5 * 10
8CFU) HpSS1 bacterium liquid, the next day 1 time, totally 3 times.2 all stochastic sampling modeling animals after the modeling behind the execution mice, are got stomach and do rapid urease test, smear Gram, pathological section and antibacterial culturing detection respectively, to guarantee the infection rate of every mice.
2, the pharmacodynamic experiment of extract of the present invention
1) experiment grouping
The helicobacter pylori infections male mice for preparing is divided into 5 groups at random, 10 every group.
2) administration
Model group: irritate stomach and only give normal saline (NS) 0.4ml/.
Positive group: CBS 6.15mg/kg, tetracycline 50mg/kg, metronidazole 22.5mg/kg; (CBS: colloidal bismuth subcitrate).
Small dose group: 75mg extract/kg;
Middle dosage group: 150mg extract/kg;
Heavy dose of group: 450mg extract/kg;
Extract adopts embodiment 4 described methods to extract to obtain in this test, chemical compound 1,2,3, and (1,2,3,6-Tetra-O-galloyl-β-D-glucose) accounts for 5.7% of extract gross mass to 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose.Each treated animal gastric infusion every day once, totally 14 days.
3) curative effect detects
Last all mices of 4 week of administration back execution.Stomach is got in dissection, vertically is cut into 4 parts along greater gastric curvature, makes rapid urease test, Gram, pathological section and antibacterial culturing respectively and detects Hp.4 kinds of equal negative patients of detection method result are decided to be the Hp feminine gender, and detection method result positive person is decided to be the Hp infection more than a kind or a kind.
3. experimental result
Anti-helicobactor pylori activity in the body of table 3. extract of the present invention
*: compare with model group; #: with the positive controls ratio.
*p＜0.05；
**p＜0.01。
4. discuss
We use the standard triple therapy the most commonly used clinically at present positive control as drug effect in the body, and the result shows: the clearance rate of accepting the positive controls helicobacter pylori infections of triple therapy is 70%, and there were significant differences with the model group ratio; Extract of the present invention clearance rate when big or middle dosage is respectively 60% and 50%, and there were significant differences with the model group ratio, do not have significant difference with the positive controls ratio simultaneously.Show that chemical compound of the present invention can effectively remove the infection of mice helicobacter pylori when dosage is 450mg/Kg, 150mg/Kg, action intensity is approaching with triple therapy commonly used at present.
The research of the laboratory animal gastric ulcer that embodiment 7 extract anti-helicobacter pyloris of the present invention cause
1 material and method
1.1 experiment material
Pallasiomy (Mongolian gerbi) MGS/Sea (SPF level) 6 ages in week,
, body weight 50g～55g.Hp SS1 bacterial strain is from microorganism institute of University of New South Wales.-70 ℃ of frozen strains are recovered containing on the Columbia agar plate of 5% horse blood, and transferred species is in having added 15% horse serum and antibiotic brain-heart-infusion.Cultivate amplification under little aerobic condition ,-80 ℃ of preservations are put in packing after urease, catalase, oxidase test and smear Gram's staining are identified.Before the inoculation antibacterial was cultivated 24-48 hour on the Skirrow selective medium, is antibacterial is centrifugal in PBS liquid, washing mixed with 3 with improved broth medium at last after evaluation and observing the antibacterial vigor? 0
11The bacterial suspension of CFU/ml, standby.
1.2 method
1.2.1 animal model pallasiomy fasting 24h, 30min irritates stomach and gives 400mL/L ethanol 0.5mL before the inoculation, above-mentioned bacterial suspension 0.5mL is irritated stomach award laboratory animal in 30min, and then fasting 4h, inoculate continuous 3d.3 months randomization part animals after the modeling are put to death, and get stomach and do rapid urease test, smear Gram, pathological section and antibacterial culturing detection, guarantee the modeling success.
1.2.2 the Hp inoculation was organized as test with the large, medium and small dosage of extract of the present invention after 3 months, triple therapy (CBS 6.15mg/kg, tetracycline 50mg/kg, metronidazole 22.5mg/kg) is as positive controls; Every day in continuous 2 weeks of gastric infusion.Stop administration after 2 weeks and raise all animals of execution after 1 month, get stomach, magnifier is measured gastric wall ulcer surface length and width down, with its product (mm
2) as ulcer index.
Extract adopts embodiment 4 described methods extractions to obtain in this test, chemical compound 1,2,3,6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose (1,2,3,6-Tetra-O-galloyl-β-D-glucose) account for 5.7% of extract gross mass, dosage is identical with the large, medium and small dosage of Herba Erodii described in the embodiment 6.
Be calculated as follows ulcer inhibition rate:
Ulcer inhibition rate (%)={ 1-(experimental group ulcer index average/matched group ulcer index mean) }? 00%; Data represent that with x Xu the relatively employing t check of group difference, variance (F value) analysis are carried out statistical procedures.
The influence of the gastric ulcer that table 4. extract of the present invention infects Hp (x ± S)
Annotate: * P＜0.05 (with comparing); * P＜0.01 (with comparing)
Result of the test shows that the big or middle dosage group of The compounds of this invention all can effectively reduce modeling animal gastric ulcer area.The action intensity of dosage group big or middle is suitable with positive group.Show that extract of the present invention can effectively treat because of the microbial digestive tract ulcer of helicobacter pylorus.
Embodiment 8, extract are to CCl
4Due to the influence of hepatic injury
60 of 18-20g Kunming mouses, male and female half and half, be divided into six groups at random by body weight: normal control group, model control group, this extract A, B, C dosage group, bifendate matched group (extract A, B, C group are respectively that wherein the content of chemical compound is respectively 2.2%, 11.4%, 5.7% according to embodiment 1,3,4 preparations).Continuous 7 days of gastric infusion (drug dose is 150mg/Kg), 2h after the last administration, all the other respectively organize ip 0.25%CCl except that the normal control group
4-olive oil 10ml/kg, the socket of the eye vein is got blood behind the 24h, and the centrifugal 15min of 2500rpm gets determination of serum ALT, and the result carries out the t check, sees Table 5.
Table 5, extract are to CCl
4Due to the influence (X ± s) of hepatic injury mice
Annotate: with the normal control group than #P＜0.05, ###P＜0.001; With the model control group ratio
*P＜0.05,
*P＜0.01,
* *P＜0.001;
By table 5 result as seen, ip in mice gives CCl
4Back Serum ALT, AST content significantly raise.The Serum ALT, the AST that give after this extract A, B, the C group mice is raise significantly reduce, and especially C group extract action intensity and positive drug bifendate are quite and be better than A, B and organize.Result of the test shows that this extract is for CCl
4Hepar damnification has obvious treatment protective effect.
Claims (10)
1. one kind is selected from thick root Herba Erodii, Carolina Cranesbill Herb, Herba Geranii eriostemonis, G.vlassouianum Fisch., Geranium tsingtauense Yabe, the extract that the plant extract of one or more in the Geranium macrorrhizum Zdravets obtains, feature is a chemical compound 1 in this extract, 2,3, the percentage ratio that 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose accounts for the extract gross mass is 1%-20%, extracting method is that plant is adopted ethanol merceration or reflux, extract, three times after crushed, the extracting solution merging is concentrated into nothing alcohol flavor, go up macroporous resin behind the thin up, water, the arbitrary concentration ethanol of 10-90% eluent eluting separates, and collection 10-90% ethanol eluent is concentrated into to be done and get; It is HPD100, HPD400, HPD600 that macroporous resin is selected from model; The concentration of alcohol of merceration or backflow is 40-80% in the leaching process.
2. the described extract of claim 1, wherein 1,2,3, the percentage ratio that 6-four-O-Galla Turcica (Galla Helepensis) acyl-β-D-glucose accounts for the extract gross mass is 2%-15%.
3. claim 1 or 2 described preparation method of extract, feature is that plant is adopted ethanol merceration or reflux, extract, three times after crushed, the extracting solution merging is concentrated into nothing alcohol flavor, go up macroporous resin behind the thin up, water, the arbitrary concentration ethanol of 10-90% eluent eluting separate, and collect 1 0-90% ethanol eluent and are concentrated into and do and get; It is HPD100, HPD400, HPD600 that macroporous resin is selected from model; The concentration of alcohol of merceration or backflow is 40-80% in the leaching process.
4. the described preparation method of claim 3, wherein the macroporous resin model is HPD100.
5. the described preparation method of claim 3, feature are to collect the eluent of 40-60% ethanol.
6. the described preparation method of claim 3, feature are to collect the eluent of 50% ethanol.
7. claim 1 or the 2 described extracts application in the medicine of the digestive tract disease that preparation anti-Helicobacter pylori infection and treatment or prevention Helicobacter pylori infection cause.
8. the described application of claim 7, wherein digestive tract disease comprises acute and chronic gastritis, superficial gastritis and stomach, the duodenal ulcer that helicobacter pylori causes.
9. claim 1 or the 2 described extracts application in the precancerous lesion medicine of tumor stomach that preparation prevention Helicobacter pylori infection causes and stomach.
10. claim 1 or the 2 described extracts application in preparation therapeutical chemistry liver damage medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101616393A CN101209271B (en) | 2006-12-29 | 2006-12-29 | Medicinal composition for preventing helicobacter pylori |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101616393A CN101209271B (en) | 2006-12-29 | 2006-12-29 | Medicinal composition for preventing helicobacter pylori |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101209271A CN101209271A (en) | 2008-07-02 |
| CN101209271B true CN101209271B (en) | 2011-06-22 |
Family
ID=39609635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101616393A Expired - Fee Related CN101209271B (en) | 2006-12-29 | 2006-12-29 | Medicinal composition for preventing helicobacter pylori |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101209271B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6839329B2 (en) * | 2017-06-06 | 2021-03-03 | サミ ラブズ リミテッド | Composition for the management of Helicobacter pylori infection |
| CN112451540B (en) * | 2020-11-25 | 2022-03-01 | 华熙生物科技股份有限公司 | Hyaluronic acid with anti-helicobacter pylori digestive tract infection activity |
| CN114480195B (en) * | 2022-02-08 | 2024-02-27 | 唐晓磊 | Quick helicobacter pylori enrichment culture reagent and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1434052A (en) * | 2003-02-12 | 2003-08-06 | 复旦大学 | Cranesbill total flavonoid extract and use in preparation of anti-virus medicine |
| CN1704064A (en) * | 2004-05-28 | 2005-12-07 | 养生堂有限公司 | Novel uses of polyhydroxy gallic acyl-beta-D-glucose derivatives |
-
2006
- 2006-12-29 CN CN2006101616393A patent/CN101209271B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1434052A (en) * | 2003-02-12 | 2003-08-06 | 复旦大学 | Cranesbill total flavonoid extract and use in preparation of anti-virus medicine |
| CN1704064A (en) * | 2004-05-28 | 2005-12-07 | 养生堂有限公司 | Novel uses of polyhydroxy gallic acyl-beta-D-glucose derivatives |
Non-Patent Citations (1)
| Title |
|---|
| 雷志勇,等.老鹳草的化学成分及药理研究进展.《中药材》.2002,第25卷(第10期),759-761. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101209271A (en) | 2008-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106963853B (en) | Total flavonoid aglycone extract of Sichuan blackberry lily and preparation method and application thereof | |
| CN101209254B (en) | New use of polyhydroxy galloyl-beta-D-glucose derivatives | |
| CN101862351A (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| CN101209271B (en) | Medicinal composition for preventing helicobacter pylori | |
| CN101805246B (en) | Urushiol compound and medicinal composition thereof, preparation method and application thereof | |
| CN101317904A (en) | Uses of smoked plum extract against virus, bacteria, mycoplasma or chlamydia of livestock and poultry | |
| CN102872015A (en) | Stephanotis total alkaloid extract as well as preparation method and application thereof | |
| CN112516205A (en) | Traditional Chinese medicine composition for treating helicobacter pylori infection | |
| KR0160108B1 (en) | Anticancer agent of raw ingredient extracted from the tree named gleditschia officinalis | |
| CN101948473B (en) | New NEO-clerodane diterpenoid compound and application thereof | |
| JP3771789B2 (en) | Gastrointestinal hyperkinetic agent | |
| WO2022151978A1 (en) | Drug for treating urolithiasis-related disease, and preparation method therefor | |
| CN103933100A (en) | Preparation method of total alkaloid of Chinese mahonia stem and applications of total alkaloid of Chinese mahonia stem in preparation of drugs for preventing and treating gastric ulcer | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN103417563A (en) | Application of aurantiamarin to preparation of medicine for treating acute and chronic bronchitis | |
| CN101336916A (en) | Use of tea polyphenol | |
| CN102125614A (en) | Preparation method of traditional Chinese medicine composition for treating common cold of children | |
| CN102008534B (en) | Antitubercular pharmaceutical composition containing balloonflower root extract | |
| CN112022892A (en) | Organic extract of plant of genus Cirsium, and application and composition thereof | |
| CN1981832A (en) | Use of cape-jasmine extract in treatment of chronic hepatitis B | |
| CN115364169B (en) | Chinese medicinal composition for resisting helicobacter pylori, and preparation method and application thereof | |
| CN1839867A (en) | Medicinal composition with heat-clearing, fire-draining and detoxification function | |
| CN112076249A (en) | Application of perilla leaf extract in preparing medicine for treating inflammatory bowel disease | |
| CN1660350A (en) | Combination of medication of containing medicinal rhubarb and activated carbon or carbo medicinalis | |
| CN113101308B (en) | Angelica gigas nakai extract and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110622 Termination date: 20181229 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |